• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
Brexpiprazole Intermediate CAS:70500-72-0
Brexpiprazole CAS:913611-97-9
3-BROMOPHENANTHRENE
2-FLUORO-4-(TRIFLUOROMETHYL)BENZOPHENONE
3-BROMO-4-FLUOROBIPHENYL
9-TRIFLUOROACETYLANTHRACENE

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing

www.nmpa.comJanuary 04, 2023

Tag: Ainuovirine , lamivudine

Recently, the innovative drug Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets (trade name:复邦德) of Jiangsu Aidea Pharmaceutical Co., Ltd. is approved by China NMPA. This product is a compound medicine composed of Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate, which is indicated for the treatment of adult HIV-1 infected patients.

The marketing of this drug provides new treatment options for adult HIV-1 infected patients.

Previous:Mobocertinib succinate capsules approved for marketing with conditions

Next:China, New Zealand to further enhance science cooperation

Related News

Thrombolytic Science Announces FDA’s IND Clearance of Mutant Prourokinase for the Treatment of Thrombotic Diseases

PharmaSourcesOctober 15, 2024

Thrombolytic Science, LLC (TSI), announced today that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for mutant prourokinase, a recombinant fibrinolytic pro-enzyme.

Eleva Appoints Dr. Elisabeth Lackner to its Supervisory Board Adding Broad Biopharmaceutical Industry Expertise to the Organization

PharmaSourcesOctober 15, 2024

BrainDos™ Formulated Dual GIP/GLP-1 Receptor Agonist Tirzepatide Outperforms Tirzepatide Solution (Mounjaro®) in Preclinical Study

PharmaSourcesOctober 15, 2024

Ainuovirine, Lamivudine and Tenofovir Disoproxil Fumarate Tablets approved for marketing - PharmaSources.com

BD and ten23 health® Partner to Advance Efficiency and Quality in Aseptic Manufacturing with RFID-Enabled Prefillable Syringes

PharmaSourcesOctober 15, 2024

BD and ten23 health today announced a collaboration to develop a new way to track prefillable syringes (PFS) using RFID technology.

You may like
More>>

Lamivudine

Lamivudine
Lamivudine Impurity J

Lamivudine Impurity J
Lamivudine api

Lamivudine api
DolutegravireLamivudine+ Tenofovir alafenamide

DolutegravireLamivudine+ Tenofovir alafenamide
Dolutegravir+Lamivudine

Dolutegravir+Lamivudine
Lamivudine*Stavudine

Lamivudine*Stavudine
Ibond® (Ainuovirine Tablets)

Ibond® (Ainuovirine Tablets)
Lamivudine USP38

Lamivudine USP38
99% up by HPLC Lamivudine 134678-17-4

99% up by HPLC Lamivudine 134678-17-4
4.4-Amino-1-(2r-hydroxymethyl-[1,3]oxathiolan-5s-yl)-1H-pyrimidin-2-one monosalicylate( lamivudine s

4.4-Amino-1-(2r-hydroxymethyl-[1,3]oxathiolan-5s-yl)-1H-pyrimidin-2-one monosalicylate( lamivudine s

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service